AstraZeneca will pay $1.2 billion upfront to CSPC for eight obesity candidates, with milestone payments potentially lifting the deal to $18.5 billion.
AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs. The R ...
A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ challenges to the Inflation Reduction Act of 2022's (IRA) Medicare Drug ...
British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England. 2014 File Photo / Agence France-Presse CHICAGO — Treating breast cancer patients with AstraZeneca’s ...